Technology | ECG | August 08, 2017

AUM Cardiovascular Receives FDA Approval for CADence ECG Device

Reusable handheld device analyzes acoustic data from patient’s heart to help physicians noninvasively detect physiological and pathological heart murmurs

AUM Cardiovascular Receives FDA Approval for CADence ECG Device

August 8, 2017 — AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a non-invasive acoustic and electrocardiogram (ECG) device designed to help physicians detect physiological and pathological heart murmurs.

The reusable, non-invasive, radiation-free handheld device, which is now available in the United States, records sounds originating from the patient's heart. Powered by a proprietary algorithm, special software crunches the acoustic data that is presented in a physician's report. The report allows a physician to determine the state of the patient's cardiovascular health. AUM also plans release of algorithms that crunch the same data to determine if arteries are clogged with plaque, a condition known as stenosis.

For primary care doctors, stenosis is particularly hard to detect because patients do not exhibit noticeable symptoms. Normal screening methods — measuring blood pressure and low-density lipoprotein (LDL) — are not good predictors of stenosis. Computed topography, magnetic resonance imaging and ultrasound can spot stenosis by measuring everything from thickness of artery walls to calcium deposits. But such technologies are expensive.

According to AUM's Turbulence clinical study, CADence performs just as well as a single-photon emission computed tomography (SPECT) nuclear stress test in ruling out obstructive coronary artery disease (CAD) in patients with chest pain and risk factors. AUM is pursuing clearance from FDA to market CADence for detection of CAD.

"The CADence system has the potential to dramatically enhance our ability to rule-out significant coronary artery disease and efficiently triage patients needing additional testing," said Jay Thomas, M.D., an interventional cardiologist at Harbor-UCLA Medical Center in Los Angeles, who oversaw the study.

"CADence is an exciting example of how novel technology will revolutionize patient care," Thomas said. "It is a rapid, cost-effective, radiation-free way to evaluate selected patients with chest pain.  The need for something like CADence is quite obvious considering how we have managed chest pain testing for the last twenty years."

For more information: www.aumcardio.com

Related Content

Feature | Cardiac Diagnostics | By Adam Saltman, MD, PhD

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If ...

Home May 04, 2022
Home
News | Cardiac Diagnostics

January 31, 2022 — Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken ...

Home January 31, 2022
Home
News | Cardiac Diagnostics

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

Home November 10, 2021
Home
Feature | Cardiac Diagnostics | By Dave Fornell, DAIC Editor

October 29, 2021 — A new guideline for the evaluation and diagnosis of chest pain was released this week that provides ...

Home October 29, 2021
Home
News | Cardiac Diagnostics

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used proprietary wearable cloth ...

Home October 04, 2021
Home
News | Cardiac Diagnostics

September 28, 2021 — Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a ...

Home September 28, 2021
Home
News | Cardiac Diagnostics

July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation ...

Home July 29, 2021
Home
News | Cardiac Diagnostics

July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation ...

Home July 01, 2021
Home
News | Cardiac Diagnostics

March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potential ...

Home March 08, 2021
Home
News | Cardiac Diagnostics

March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management ...

Home March 03, 2021
Home
Subscribe Now